LifeMD’s (LFMD) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of LifeMD (NASDAQ:LFMD) in a research note published on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $15.00 target price on the stock.

Other research analysts also recently issued reports about the company. Lake Street Capital initiated coverage on LifeMD in a research note on Tuesday, December 10th. They set a “buy” rating and a $12.00 target price for the company. Mizuho initiated coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of LifeMD in a research note on Monday, November 11th. Finally, KeyCorp reduced their target price on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $11.43.

LifeMD Trading Down 1.9 %

Shares of NASDAQ LFMD opened at $5.66 on Tuesday. LifeMD has a 1 year low of $3.99 and a 1 year high of $12.88. The firm’s 50-day moving average is $5.68 and its 200-day moving average is $5.38. The firm has a market capitalization of $245.15 million, a PE ratio of -8.84 and a beta of 1.50.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $64.26 million during the quarter, compared to analyst estimates of $57.43 million. As a group, equities research analysts anticipate that LifeMD will post -0.56 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Justin Schreiber sold 50,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total value of $377,500.00. Following the transaction, the chief executive officer now owns 2,653,715 shares in the company, valued at $20,035,548.25. The trade was a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 15.97% of the company’s stock.

Institutional Investors Weigh In On LifeMD

Large investors have recently bought and sold shares of the stock. Intech Investment Management LLC acquired a new stake in LifeMD in the 3rd quarter valued at $54,000. ProShare Advisors LLC bought a new position in shares of LifeMD in the fourth quarter valued at $51,000. Balyasny Asset Management L.P. acquired a new position in shares of LifeMD during the fourth quarter valued at about $52,000. Oxford Asset Management LLP acquired a new position in shares of LifeMD during the fourth quarter valued at about $52,000. Finally, AXQ Capital LP bought a new stake in shares of LifeMD during the fourth quarter worth about $57,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.